Inventiva Sa company info

What does Inventiva Sa do?
Inventiva (EPA:IVA), (NASDAQ:IVA) is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical need, particularly in the realms of fibrosis, lysosomal storage disorders, and oncology. Its pipeline is led by lanifibranor, which is in Phase IIb development for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. Inventiva is also advancing a second candidate, odiparcil, aimed at treating patients with mucopolysaccharidosis, a group of lysosomal storage disorders. With each project, Inventiva aims to leverage its expertise in nuclear receptor, transcription factor, and epigenetics to discover and develop novel therapeutics. The company is also listed on the Euronext Paris under the ticker (EPA:IVA), indicating its commitment to expanding its reach and enhancing shareholder value through multiple market presences.
Inventiva Sa company media
Company Snapshot

Is Inventiva Sa a public or private company?

key
Ownership
Public

How many people does Inventiva Sa employ?

people
Employees
122

What sector is Inventiva Sa in?

pie chart
Sector
Health Care

Where is the head office for Inventiva Sa?

location pin
Head Office
Daix, France

What year was Inventiva Sa founded?

founded flag
Year Founded
2011
What does Inventiva Sa specialise in?
/Pharmaceutical Research /Fibrosis Treatments /NASH Therapeutics /Drug Development /Clinical Trials /Biotechnology Innovation

What are the products and/or services of Inventiva Sa?

Overview of Inventiva Sa offerings
Lanifibranor, a treatment targeting non-alcoholic steatohepatitis (NASH) and other fibrotic diseases.
Research focusing on the development of drugs leveraging the YAP-TEAD transcriptional complex for fibrotic conditions.
Partnerships for innovative therapies in fibrosis and rare diseases.
Odiparcil, a therapy aimed at treating mucopolysaccharidoses.
A range of preclinical candidates addressing various fibrotic diseases.
Technology platforms for drug discovery, including YAP-TEAD inhibitors.

Who is in the executive team of Inventiva Sa?

Inventiva Sa leadership team
  • Dr. Pierre  Broqua Ph.D.
    Dr. Pierre Broqua Ph.D.
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
  • Mr. Frederic  Cren
    Mr. Frederic Cren
    Co-Founder, CEO & Chairman
  • Mr. Jean  Volatier
    Mr. Jean Volatier
    Deputy GM & CFO
  • Ms. Alice  Roudot-Ketelers Pharm.D.
    Ms. Alice Roudot-Ketelers Pharm.D.
    Chief Operating Officer
  • Mr. Eric  Duranson L.L.M.
    Mr. Eric Duranson L.L.M.
    General Counsel
  • Ms. Nathalie  Harroy
    Ms. Nathalie Harroy
    Head of Human Resources
  • Dr. Michael  Cooreman
    Dr. Michael Cooreman
    Chief Medical Officer
  • Ms. Pascaline  Clerc Ph.D.
    Ms. Pascaline Clerc Ph.D.
    Executive Vice President of Strategy & Corporate Affairs